NCT05161325View on ClinicalTrials.gov

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan

Active, not recruitingOBSERVATIONAL
Enrollment

525

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

June 1, 2026

Conditions
Non-Small Cell Lung Cancer
Trial Locations (1)

1070052

Local Institution, Minato-ku

Sponsors

Collaborators (1)

Ono Pharma USA Inc
All Listed Sponsors
collaborator

Ono Pharma USA Inc

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT05161325 - A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan | Biotech Hunter | Biotech Hunter